α1-antitrypsin deficiency: Situation in Spain and development of a screening program;Déficit de alfa-1-antitripsina. Situación en España y desarrollo de un programa de detección de casos

Archivos de Bronconeumologia

Volumn 42, Issue 6, 2006, Pages 290-298

  De La Roza, Cristian ^a   Lara, Beatriz ^a   Vilà, Sara ^a   Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

COPD; Diagnosis; Prevalence

Indexed keywords

TOBACCO SMOKE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; ENVIRONMENTAL FACTOR; GENOTYPE; HEREDITY; HUMAN; LUNG EMPHYSEMA; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREVALENCE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SCREENING; SMOKING; SPAIN; WORLD HEALTH ORGANIZATION;

EID: 33745924405     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13089541     Document Type: Review

References (88)

1. Sobradillo V, Miravitlles M, Gabriel R, Jiménez-Ruiz C, Villasante C, Masa JF, Viejo JL, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981-9.
2. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am. 1996;80:501-22.
3. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis. An eight year follow up study of working men in London. Oxford: Oxford University Press; 1976.
4. Bascom R. Differential susceptibility to tobacco smoke: possible mechanism. Pharmacogenetics. 1991;1:102-6.
5. Tager IB, Rosner B, Tishler PV, Speizer FE. Household aggregation of pulmonary function and chronic bronchitis. Am Rev Respir Dis. 1976;114:485-92.
6. Tager IB, Tishler PV, Rosner B, Speizer FE. Studies of the familial aggregation of chronic bronchitis and obstructive airways disease. Int J Epidemiol. 1986;15:65-72.
7. Cohen BH, Diamond EL, Graves CG. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet. 1977;10:523-6.
8. Higgins M, Keller J. Familial occurrence of chronic respiratory disease and familial resemblance in ventilatory capacity. J Chron Dis. 1975;28:239-51.
9. Kauffmann F, Tager IB, Muñoz A, Speizer FE. Familial factors related to lung function in children aged 6-10 years. Am J Epidemiol. 1989;129:1289-99.
10. Devor EJ, Crawford MH. Family resemblance for normal pulmonary function. Ann Hum Biol. 1984;11:439-48.
11. Rybicki BA, Beaty TH, Cohen BH. Major genetic mechanisms in pulmonary function. J Clin Epidemiol. 1990;43:670-5.
12. Astemborski JA, Beaty TH, Cohen BH. Variance components analysis of forced expiration in families. Am J Med Genet. 1985;21:741-53.
13. Redline S, Tishler PV, Rosner B, Lewitter FI, Vandenburg M, Weis ST, et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. Am J Epidemiol. 1989;129:827-36.
14. Zamel N, Webster P, Lorimer E, Man S. Environment versus genetics in determining bronchial susceptibility to cigarette smoking. Chest. 1981;80:57S.
15. Man SFP, Zamel N. Genetic influences on normal variability of maximum expiratory flow-volume curves. J Appl Physiol. 1976;41:874-7.
16. Silverman E, Chapman H, Drazen J. Early-onset chronic obstructive pulmonary disease (COPD): preliminary evidence for genetic factors other than Pi type. Am J Respir Crit Care Med. 1996;153:A48.
17. Miravitlles M, Vidal R, De Gracia J. Enfisema por déficit de alfa-1 antitripsina. Situación actual y nuevas perspectivas para el tratamiento. Arch Bronconeumol. 1992;28:296-302.
18. Laurell CB, Erikson S. The electrophoretic alpha1 globulin pattern of serum in alpha1 antitrypsin deficiency. Scan J Clin Invest. 1963;15:132-40.
19. Mornex JF, Chytil-Weir A, Martinet Y, Courtney M. Expression of the alpha1 antitrypsin gene in mononuclear phagocytes of normal and alpha1 antitrypsin deficient individuals. J Clin Invest. 1986;77:1952-61.
20. Cox DW, Johnson AM, Fagerhol MK. Report of nomenclature meeting for alpha1 antitrypsin. Hum Genet. 1980;53:429-33.
21. Fagerhol MK, Laurell CB. The Pi system: inherited variants of serum alpha1 antitrypsin. Prog Med Genet. 1970;7:96-111.
22. Allen RC, Harley RA, Talamo RC. A new method for determination of alpha1 antitrypsin phenotypes using isoelectric focusing on polyacrylamide gel slabs. Am J Clin Pathol. 1974;62:732-9.
23. Birrer P, McElvaney NG, Crystal RG. Alpha1 antitrypsin deficiency and liver disease. J Inher Metab Dis. 1991;14:512-25.
24. Blanco I, Fernández E. Alpha-1 antitrypsin Pi phenotypes S and Z in Spain: an analysis of the published surveys. Respir Med. 2001;95:109-14.
25. Vidal R, Miravitlles M, Jardí R, Torrella M, Rodríguez- Frías F, Moral P, et al. Estudio de la frecuencia de los diferentes fenotipos de la alfa-1-antitripsina en una población de Barcelona. Med Clin (Barc). 1996;107:211-4.
26. Lieberman J, Winter B, Sastre A. Alpha antitrypsin Pi-types in 965 COPD patients. Chest. 1986;89:370-3.
27. Álvarez-Granda L, Cabero-Pérez MJ, Bustamante-Ruiz A, Gonzalez Lamuño D, Delgado Rodríguez M, García Fuentes M. Pi SZ phenotype in chronic obstructive pulmonary disease. Thorax. 1997;52:659-61.
28. Hutchinson DCS, Tobin MJ, Cook PJL. Alpha-1 antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. A survey by the British Thoracic Association. Br J Dis Chest. 1983;77:28-34.
29. Turino GM, Barker AF, Brantly ML. Clinical features of individuals with Pi SZ phenotype of alpha1 antitrypsin deficiency. Am J Respir Crit Care Med. 1996;154:1718-25.
30. Larsson C, Dirksen H, Sunstrom G, Eriksson S. Lung function studies in asymptomatic individuals with moderately (Pi SZ) and severely (PiZ) reduced levels of alpha one antitrypsin. Scand J Respir Dis. 1976;57:267-80.
31. Dahl M, Hersh CP, Ly NP, Berkey C, Silverman E, Nordestgaard B. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J. 2005;26:67-76.
32. Holmes MD, Brantly ML, Crystal RG. Molecular analysis of the heterogeneity among the P-family of alpha-1-antitrypsin alleles. Am Rev Respir Dis. 1990;142:1185-92.
33. Faber JP, Weidinger S, Goedde HW, Ole K. The deficient alpha-1-antitrypsin phenotype PI P is associated with an A-to-T transversion in exon III of the gene. Am J Hum Genet. 1989;45:161-3.
34. Hildesheim J, Kinsley G, Bissell M, Pierce J, Brantly M. Genetic diversity from a limited repertoire of mutations on different common allelic backgrounds: alpha 1-antitrypsin deficiency variant Pduarte. Hum Mutat. 1993;2:221-8.
35. Jardí R, Rodríguez-Frías F, Casas F, Cotrina M, Vidal R, Miravitlles M, et al. Caracterización molecular de 2 variantes del déficit de alfa-1-antitripsina: PI Mpalermo y PIPlovel. Med Clin (Barc). 1997;109:463-6.
36. Faber JP, Poller W, Weidinger S, Kirchgesser M, Schwaab R, Bidlingmaier F, et al. Identification and DNA sequence analysis of 15 new alpha 1-antitrypsin variants, including two PI*Q0 alleles and one deficient PI*M allele. Am J Hum Genet. 1994;55:1113-21.
37. Jardí R, Rodríguez Frías F, López Talavera JC, Miravitlles M, Cortina M, Costa X, et al. Characterization of the new alpha1 antytrypsin deficient Pi M type allele, Pi Mvall d'hebron (Pro369Ser). Hum Hered. 2000;50:320-1.
38. Jardí R, Rodríguez F, Miravitlles M, Vidal R, Cotrina M, Quer J, et al. Identification and molecular characterization of the new alpha-1-antitrypsin deficient allele PI Y barcelona (Asp256→Va1 and Pro391→His). Hum Mutat. 1998;12:213.
39. Miravitlles M, Vila S, Jardí R, De la Roza C, Rodríguez- Frías F, Vidal R. Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant. Chest. 2003;124:404-6.
40. Black LF, Kueppers F. Alpha1 antitrypsin deficiency in nonsmo-kers. Am Rev Respir Dis. 1978;117:421-8.
41. Janus ED, Philips NT, Carrell RW. Smoking, lung function and alpha1 antitrypsin deficiency. Lancet. 1985;19:152-4.
42. Brantly ML, Paul LD, Miller BH, Falk RT, Wu M. Clinical features and history of the destructive lung disease associated with alpha1 antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988;138:327-36.
43. Tobin MJ, Cook PJL, Hutchinson DCS. Alpha1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z; a survey by the British Thoracic Association. Br J Dis Chest. 1983;77:14-27.
44. Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha1 antitrypsin deficiency with special reference to non-index cases. Thorax. 1994;49:695-8.
45. Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med. 1989;111:982-91.
46. Novoradovsky A, Brantly ML, Waclawiw MA. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1 antitrypsin deficiency. Am J Respir Cell Mol Biol. 1999;20:441-7.
47. Terrier P, Townsend AJ, Coindre JM, Triche TJ, Cowan KH. An immunohistological study of Pi class glutathione S-transferase expression in normal human tissue. Am J Patol. 1990;137:845-53.
48. Sunberg AGM, Nilsson R, Appelkvist EL, Dallner G. Immunohistochemical location of alpha and mu class glutathione transferases in normal tissues. Pharmacol Toxicology. 1993;72:321-31.
49. Whalen R, Boyer T. Human glutathione S-transferases. Semin Liver Dis. 1998;18:345-58.
50. Rodríguez F, De la Roza C, Jardí R, Schaper M, Vidal R, Miravitlles M. Glutathione S-transferase PI and lung function in patients with alpha-1 antitrypsin deficiency. Chest. 2005;127:1537-43.
51. De Serres FJ. Worldwide racial and ethnic distribution of alpha-1 antitrypsin deficiency. Chest. 2002;122:1818-29.
52. Blanco I, Fernández-Bustillo E, De Serres FJ, Alkassam D, Rodríguez Menéndez C. Déficit de alfa-1-antitripsina en España (variantes deficientes PI*S y PI*Z): prevalencia estimada y número de sujetos calculados para cada fenotipo. Med Clin (Barc). 2004;123:761-5.
53. Vidal R, Miravitlles M y Grupo de Estudio del Déficit de Alfa-1-antitripsina. Informe del Registro Español de Pacientes con Déficit de Alfa-1-antitripsina. Arch Bronconeumol. 1995;31:299-302.
54. Miravitlles M, Vidal R, Barros-Tizón JC, Bustamante A, España PP, Casas F, et al. Usefulness of a national Registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir Med. 1998;92:1181-7.
55. Miravitlles M, Vidal R, Barros-Tizón JC, Bustamante A, España PP, Casas F, et al. Estado actual del tratamiento sustitutivo en el enfisema congénito por déficit de alfa-1-antitripsina. Informe del Registro Nacional. Arch Bronconeumol. 1999;35:446-54.
56. Hutchinson D. Alpha-1 antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir Med. 1998;92:367-77.
57. nd meeting of the Alpha One International Registry. Rapallo (Genoa, Italy). 2001. Eur Respir J. 2002;20:1050-6.
58. Sandford AJ, Weir TD, Paré PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J. 1997;10:1380-91.
59. Bruce RM, Cohen BH, Diamond EL, et al. Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects. Am Rev Respir Dis. 1984;130:386-90.
60. Pride NB, Tattersall SF, Pereira RP, Hunter D, Blundell G. Lung distensibility and airway function in intermediate alpha 1-antitrypsin deficiency (PiMZ). Chest. 1980;77 2 Suppl:253-5.
61. Horton FO III, Mackenthun AV, Anderson PS Jr, Patterson CD, Hammarsten JF. Alpha 1 antitrypsin heterozygotes (Pi type MZ). A longitudinal study of the risk of development of chronic air flow limitation. Chest. 1980;77 2 Suppl:261-4.
62. Cooper DM, Hoeppner V, Cox D, Zamel N, Bryan AC, Levison H. Lung function in alpha1-antitrypsin heterozygotes (Pi type MZ). Am Rev Respir Dis. 1974;110:708-15.
63. Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin mz heterozygotes: a longitudinal study of the general population. Ann Intern Med. 2002;136:270-9.
64. Mittman C, Lieberman J, Rumsfeld J. Prevalence of abnormal protease inhibitor phenotypes in patients with chronic obstructive lung disease. Am Rev Respir Dis. 1974;109:295-6.
65. Barnett TB, Gottovi D, Johnson AM. Protease inhibitors in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1975;111:587-93.
66. Cox DW, Hoeppner VH, Levison H. Protease inhibitors in patients with chronic obstructive pulmonary disease: the alpha-antitrypsin heterozygote controversy. Am Rev Respir Dis. 1976;113:601-6.
67. Shigeoka JW, Hall WJ, Hyde RW, Schwartz RH, Mudholkar GS, Speers DM, et al. The prevalence of alpha-antitrypsin heterozygotes (Pi MZ) in patients with obstructive pulmonary disease. Am Rev Respir Dis. 1976;114:1077-84.
68. Bartmann K, Fooke M, Koch G, Schutz I, Weis E, Zierski M. Heterozygosity in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD). Eur J Respir Dis. 1985;66:284-96.
69. Janus ED. Alpha 1-antitrypsin Pi types in COPD patients. Chest. 1988;94:446-7.
70. De Serres FJ. Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environ Health Perspect. 2003;111:1851-4.
71. Katz RM, Lieberman J, Siegel SC. Alpha-1 antitrypsin levels and prevalence of Pi variant phenotypes in asthmatic children. J Allergy Clin Immunol. 1976;57:41-5.
72. Colp C, Talavera W, Goldman D, Green J, Multz A, Lieberman J. Profile of bronchospastic disease in Puerto Rican patients in New York City. A possible relationship to alpha 1-antitrypsin variants. Arch Intern Med. 1990;150:2349-54.
73. Miravitlles M, Vila S, Torrella M, Balcells E, Rodríguez- Frías F, De la Roza C, et al. Influence of deficient alpha 1-anti-trypsin phenotypes on clinical characteristics and severity of asthma in adults. Respir Med. 2002;96:186-92.
74. McElvaney NG, Stoller JK, Buist AS, Prakash UBS, Brantly ML, Schluchter MD. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha-1-antitrypsin deficiency. Chest. 1997;111:394-403.
75. Barbera JA, Peces-Barba G, Agustí A, Izquierdo JL, Monsó E, Montemayor T, Viejo JL. Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva cronica. Arch Bronconeumol. 2001;37:297-316.
76. Miravitlles M, Vidal R, Torrella M, Bofill JM, Cotrina M, De Gracia J. Evaluación del tratamiento sustitutivo del enfisema por déficit de alfa-1 antitripsina. Arch Bronconeumol. 1994;30:479-84.
77. 1-antitrypsin deficiency. Ann Allergy. 1994;72:105-11.
78. Miravitlles M, Jardí R, Rodríguez-Frías F, Torrella M, Pelegrí D, Vidal R. Utilidad de la cuantificación de la banda alfa-1 del proteinograma sérico en el cribado del déficit de alfa-1 antitripsina. Arch Bronconeumol. 1998;34:536-40.
79. Alpha 1 antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75:397-415.
80. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900.
81. Luisetti M, Massi G, Massobrio M, Guarraci P, Menchicchi M. A national program for detection of alpha 1-antitrypsin deficiency in Italy. Respir Med. 1999;93:169-72.
82. Wencker M, Marx A, Konietzko N, Schaefer B, Campbell EJ. Screening for alpha1-Pi deficiency in patients with lung diseases. Eur Respir J. 2002;20:319-24.
83. Brantly M, Mishra V, Zienko L. Statewide targeted screening and detection of AAT deficiency. Am J Respir Crit Care Med. 2003;167:A222.
84. De la Roza C, Rodríguez-Frías F, Lara B, Vidal R, Jardí R, Miravitlles M. Results of a case-detection program for alpha-1 antitrypsin deficiency in COPD patients. Eur Respir J. 2005;26:216-22.
85. Costa X, Jardí R, Rodríguez F, Miravitlles M, Cotrina M, Pascual C, et al. Easy method for screening dried blood spot specimens on filter paper for alpha-1 antitrypsin deficiency. Eur Respir J. 2000;15:1111-5.
86. Rodríguez F, Jardí R, Costa X, Cotrina M, Galimany R, Vidal R, et al. Rapid screening for alpha 1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. Am J Respir Crit Care Med. 2002;166:814-7.
87. 1-antitripsina en pacientes con EPOC mediante el uso de gota de sangre en papel secante. Arch Bronconeumol. 2003;39:8-12.
88. Miravitlles M. Enfisema por deαficit de alfa-1 antitripsina: ¿es realmente una enfermedad infrecuente? Med Clin (Barc). 2004;123:778-9.